ARTIDIS Meets Primary Endpoints in First Prospective Study

Our portfolio company ARTIDIS announces today promising data from their first prospective study conducted at the Breast Center in Basel, Switzerland. The spin-off from the Biozentrum at the University of Basel has succesfully developed the first nanomechanical biomarker for cancer diagnosis and treatment optimization.  HEMEX AG is a privately-owned Swiss investment and consulting company headquartered […]

ARTIDIS Gains Momentum in 2019 Raising CHF 8.8 Million in Seed Financing

Startup off the ground

ARTIDIS AG, a privately held healthtech company, announced today the successful closure of a CHF 8.8 million seed financing in two rounds securing early clinical validation and the next development phase towards market entry in 2021. The funding will be used to advance the company’s healthtech platform into a large multi-centre clinical study together with […]

Artidis: Cancer diagnosis in less than 3 hours

Marija Plodinec, CEO of Artidis (Img: Technologiepark Basel) “Artidis is based on the oldest diagnostic test on earth: palpation,” says Marija Plodinec, CEO and co-founder of Artidis AG. “In a nutshell, we palpate tissue on a molecular level,“ she adds with a twinkle. That’s because instead of a physician’s hand, Artidis runs a fine, high-precision […]

LK-01 Granted Orphan Drug Designation by the U.S. FDA for Acute Myeloid Leukemia

BARCELONA, Spain – Leukos Biotech, a spin-off company founded by the Barcelona based Jose Carreras Leukaemia Research Institute and supported by VCF Inveready, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for LK-01, a product based on Apomorphine, for the treatment of Acute Myeloid Leukemia. Acute Myeloid Leukaemia (AML) is […]